The Zydus Lifesciences date has been confirmed from February 29, 2024 – March 6, 2024.
Zydus Lifesciences Limited, a well-established player in the Indian pharmaceutical market, provides healthcare services globally. Within its repertoire, the company develops formulations, APIs, vaccines, biosimilars, and a range of complex products spanning transdermal, topical, and animal health sectors, as well as wellness goods.
Start your investing journey today. How do you open your own demat account for free?
Buyback Dates
Feb 29 – Mar 6
Buyback Price
₹1005 per share
Face Value
₹1 per share
Offer Closes On
March 6, 2024
Zydus Lifesciences Buyback Price
The Zydus Lifesciences Buyback Price is ₹1005 per share.
IPO Overview
Zydus Lifesciences Limited, an Indian pharmaceutical giant, is recognized globally for its healthcare offerings. This business fabricates formulations, APIs, vaccines, biosimilars, intricate items like transdermal and topical goods, animal health treatments, and wellness solutions. Zydus Lifesciences Limited maintains an extensive manufacturing footprint, with over 30 plants situated in India, Germany, Brazil, and the United States. Zydus Lifesciences Limited holds the distinction of being the fourth-largest pharmaceutical entity in India. Zydus Lifesciences emerged from the former identity of Cadila Healthcare Limited.
Zydus Lifesciences Buyback Details
| Issue Period | February 29, 2024 – March 6, 2024 |
| Security Name | Zydus Lifesciences Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 5,970,149 (0.59 % of Total number of equity Shares) |
| Issue Size (Amount) | ₹600.00 Crores |
| Buyback Price | ₹1005 per share |
| Face Value | ₹1 per share |
| Listing At | BSE, NSE |
Zydus Lifesciences Limited Financial Information
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Revenue | 9,553.50 | 8,160.60 | 7,869.30 |
| Profit After Tax | 1,529.20 | 857.90 | 1,476.20 |
| Net Worth | 17,515.80 | 16,999.60 | 12,992.30 |
| Reserves and Surplus | 1,801.75 | ||
| Total Borrowing | 1,163.20 | 4,196.00 | 4,583.50 |
| Amount in ₹ Crore | |||
Zydus Lifesciences Buyback Issue Timetable
| Last Date to buy shares | February 22, 2024 |
| Record Date | February 23, 2024 |
| Offer Opens On | February 29, 2024 |
| Last Date for receipt of Tender Forms | March 6, 2024 |
| Offer Closes On * | March 6, 2024 |
| Finalisation of Buyback Acceptance | March 13, 2024 |
| Last Date for settlment of bids | March 14, 2024 |
| Last Date for Extinguishment of Shares | March 26, 2024 |
Company Profile
Necessity of the Issue
The Buyback will help the company to distribute a part of the surplus cash to its shareholders holding equity shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders’ value in the longer term, and improving the return on equity.
Registrar Info
| Name | Link Intime India Private Ltd |
| Phone number | +91-22-4918 6270 |
| Email ID | zyduslife.buyback2024@linkintime.co.in |
| Website | linkintime.co.in |
Contact Details
| Name | Zydus Lifesciences Limited |
| Phone number | +91-79-71800000 |
| Email ID | dhavalsoni@zyduslife.com |
| Website | zyduslife.com |
IPO Strengths
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
